Imperial Brands: Neutral Performance with Positive Investor Sentiment

Business by 2FIRSTS.ai

Jan.23.2024

Imperial Brands: Neutral Performance with Positive Investor Sentiment

According to German media aktiencheck, the 200-day moving average of Imperial Brands stock is currently at £1798.17.

According to reports from German media outlet Aktiencheck on January 23, the 200-day moving average for Imperial Brands' stock currently stands at £1798.17. Considering that the current stock price stands at £1881, this indicates a gap of +4.61%. Compared to other stocks in the consumer goods sector, Imperial Brands' earnings last year were 6% lower than the average level. However, within the tobacco industry, the stock's earnings outperformed the average level by 3.38%. As a result, the overall assessment is deemed to be "neutral".

It is worth noting that the 50-day moving average price stands at £1,836.3 with a corresponding difference of +2.43%, further reinforcing the "neutral" assessment.

Based on investor sentiment, there is currently a relatively positive attitude towards the Empire brand, with 12 positive and 1 negative feedbacks recorded recently. Considering the company's latest developments showing a proactive performance, the overall sentiment analysis rates it as "good".

References:

[1] Imperial Brands Aktie: Quo vadis?

Also Read:

[1] BLU Launches E-Liquid Brand "blu liquid" in UK

[2] Analysis of Imperial Tobacco Stock: Good Rating, Neutral Outlook

#Europe #Traditional tobacco #Market #Imperial Brands #Germany #Brands

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

CSUR, the Research Institute Supporting Juul’s PMTA Research, Outlines a New Pathway for Nicotine Pouches

CSUR—the Research Institute Supporting Juul and NJOY’s successful PMTAs—assessed FDA’s pilot for nicotine pouches. The program expedites premarket review by deferring behavioral data to post-market reporting. CSUR says this could speed authorizations, but manufacturers must still produce behavioral and real-world evidence after a Marketing Granted Order to maintain compliance with public-health standards.

Nov.04

Australia Leads COP11 Seminars as Exploding Illicit Tobacco Market Raises Questions

Australia sent a delegation to COP11 in Switzerland and is leading three major seminars to showcase its vape and tobacco control policies. But at home, illicit cigarette sales are skyrocketing amid record-high taxes, drawing criticism from the tobacco industry and prompting doubts over policy effectiveness.

Nov.20 by 2FIRSTS.ai

ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting

The U.S. FDA has scheduled a Tobacco Products Scientific Advisory Committee (TPSAC) meeting for January 22, 2026, to review Swedish Match USA’s Modified Risk Tobacco Product (MRTP) applications for 20 ZYN nicotine pouch products. Although the products gained PMTA authorization in early 2025, MRTP approval is required for marketing them with reduced-risk claims.

Nov.24 by 2FIRSTS.ai

KT&G to Complete New Indonesian Factory, Its Largest Overseas Production Hub

According to Daily Hankooki, KT&G’s new factory in Indonesia will be completed this month and is scheduled to begin operations in February 2026. Once operational, the facility will have an annual production capacity of around 35 billion cigarettes, becoming the company’s largest overseas manufacturing base.